Homocysteine and copper interact to promote type 5 phosphodiesterase expression in rabbit cavernosal smooth muscle cells

Asian Journal of Andrology

Volumn 10, Issue 6, 2008, Pages 905-913

  Hotston, Matthew ^a   Jeremy, Jamie Y ^a   Bloor, Jonathon ^a   Greaves, Nick S ^a   Persad, Raj ^a   Angelini, Gianni ^a   Shukla, Nilima ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

APOCYNIN; CATALASE; COPPER CHLORIDE; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; HOMOCYSTEINE; PHOSPHODIESTERASE V; SILDENAFIL; SUPEROXIDE DISMUTASE; CHELATING AGENT; COPPER; PENICILLAMINE; PHOSPHODIESTERASE INHIBITOR; PIPERAZINE DERIVATIVE; PURINE DERIVATIVE; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SULFONE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; ERECTILE DYSFUNCTION; NONHUMAN; PENIS; PHARMACOLOGICAL BLOCKING; PROTEIN EXPRESSION; REGULATORY MECHANISM; SMOOTH MUSCLE FIBER; UPREGULATION; VASCULAR SMOOTH MUSCLE; WESTERN BLOTTING; ANIMAL; BIOSYNTHESIS; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; GENE EXPRESSION REGULATION; IN VITRO STUDY; MALE; METABOLISM; RABBIT; STATISTICAL ANALYSIS;

ANIMALS; BLOTTING, WESTERN; CHELATING AGENTS; COPPER; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 5; DATA INTERPRETATION, STATISTICAL; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HOMOCYSTEINE; MALE; MYOCYTES, SMOOTH MUSCLE; NADPH OXIDASE; PENICILLAMINE; PENIS; PHOSPHODIESTERASE INHIBITORS; PIPERAZINES; PURINES; RABBITS; REACTIVE OXYGEN SPECIES; SULFONES;

EID: 59449087505     PISSN: 1008682X     EISSN: 17457262     Source Type: Journal    
DOI: 10.1111/j.1745-7262.2008.00380.x     Document Type: Article

References (42)

1. Andersson KE. Pharmacology of penile erection. Pharmacol Rev 2001; 53: 417-50.
2. Lue TF. Erectile dysfunction. N Engl J Med 2000; 432: 1802-13.
3. Moore CR, Wang R. Pathophysiology and treatment of diabetic erectile dysfunction. Asian J Androl 2006; 8: 675-84.
4. Jones RW, Rees RW, Minhas S, Ralph D, Persad RA, Jeremy JY. Oxygen free radicals and the penis. Expert Opin Pharmacother 2002; 3: 889-97.
5. Jeremy JY, Jones RA, Koupparis AJ, Hotston M, Persad R, Shukla N. Oxidative stress and erectile dysfunction: Possible role of NADPH oxidase. Int J Impot Res 2006: 175: 1175-6.
6. Muzaffar S, Jeremy JY. NADPH oxidases: A promiscuous target for cardiovascular drugs? Trends Cardiovasc Med 2005; 15: 278-82.
7. phox NADPH oxidase induced by the thromboxane A2 mimetic, U46619, in corpus cavernosal smooth muscle cells. BJU Int 2005; 96: 423-7.
8. Shukla N, Jones R, Persad R, Angelini GD, Jeremy JY. Effect of sildenafil citrate and a nitric oxide donating sildenafil derivative, NCX 911, on cavernosal relaxation and superoxide formation in hypercholesterolaemic rabbits. Eur J Pharmacol 2005; 517: 224-31.
9. Koupparis A, Jeremy JY, Persad N, Angelini GD, Shukla N. Penicillamine administration reverses the inhibitory effect of hyperhomocysteinaemia on endothelium-dependent relaxation in the corpus cavernosum in the rabbit. BJU Int 2006; 98: 440-4.
10. Jeremy JY, Koupparis A, Muzaffar S, Persad R, Angelini GD, Shukla N. Is the therapeutic action of sildenafil mediated partly through the inhibition of superoxide formation? BJU Int 2005; 95: 930-1.
11. phox expression in porcine pulmonary artery endothelial cells. Br J Pharmacol 2005: 146: 109-17.
12. Jacobsohn K, Wang R. Evaluation and diagnostic testing of erectile dysfunction in the era of phosphodiesterase type 5 inhibitors. Asian J Androl 2007; 9: 3-7.
13. Yip WC, Chiang HS, Mendoza JB, Tan HM, Li MK, Wang WC, et al. Efficacy and safety of on demand tadalafil in the treatment of East and Southeast Asian men with erectile dysfunction: A randomized double-blind, parallel, placebo-controlled clinical study. Asian J Androl 2006; 8: 685-92.
14. Yu JY, Kang KK, Yoo M. Erectile potentials of a new phosphodiesterase type 5 inhibitor, DA-8159, in diet-induced obese rats. Asian J Androl 2006; 8: 325-9.
15. Carson CC, Lue TF. Phosphodiesterase type 5 inhibitors for erectile dysfunction. BJU Int 2005; 96: 257-80.
16. Jeremy JY, Ballard S, Naylor A, Angelini GD. Effect of sildenafil (Viagra), a specific inhibitor of cGMP phosphodiesterase, on cAMP and cGMP formation by the rabbit corpus cavernosa, in vitro. Br J Urol 1997; 79: 958-63.
17. Hotston M, Jeremy JY, Kouparris A, Persad N, Angelini GD, Shukla N. Sildenafil (Viagra) inhibits the upregulation of type 5 phosphodiesterase elicited with nicotine and tumour necrosing factor-α in cavernosal vascular smooth muscle cells: Mediation by superoxide. BJU Int 2007; 99: 612-8.
18. Jones RW, Jeremy JY, Persad R, Angelini GD, Shukla N. Erectile dysfunction in hyperhomocysteinaemic rabbits. Br J Urol 2005; 95: 125-30.
19. Khan M, Thompson CS, Emsley A, Morgan RJ, Angelini GD, Jeremy JY. Homocysteine and copper interact to markedly inhibit the relaxation of the rabbit corpus cavernosum. New risk factors for angiopathic erectile dysfunction? Br J Urol 1999: 84: 720-4.
20. Emsley A, Jeremy JY, Gomes G, Angelini GD, Plane F. Copper interacts with homocysteine to inhibit nitric oxide formation in the rat isolated aorta. Br J Pharmacol 1999; 126: 1034-40.
21. 2α in cultured porcine pulmonary artery vascular smooth muscle cells. Br J Pharmacol 2004; 141: 488-96.
22. Muzaffar S, Jeremy JY, Angelini GD, Stuart-Smith K, Shukla N. The role of the endothelium and nitric oxide synthases in modulating superoxide formation induced by endotoxin and cytokines in porcine pulmonary arteries. Thorax 2003; 58: 598-604.
23. Jeremy JY, Shukla N, Angelini GD, Wan I, Ascione R. Sustained increases in homocysteine, copper and ceruloplasmin following coronary artery bypass grafting. Ann Thorac Surg 2002; 74: 1553-7.
24. Berwanger CS, Jeremy JY, Stansby G. Homocysteine and vascular disease. Br J Surg 1995; 82: 726-31.
25. Muzaffar S, Shukla N, Angelini GD, Jeremy JY. Nitroaspirins and SIN-1, but not aspirin, inhibit the expression of endotoxin- and cytokine-induced NADPH oxidase in vascular smooth muscle cells from pig pulmonary arteries. Circulation 2004; 110: 1140-7.
26. Muzaffar S, Shukla N, Angelini GD, Jeremy JY. Superoxide auto-augments superoxide formation and upregulates gp91 (phox) expression in porcine pulmonary artery endothelial cells: Inhibition by iloprost. Eur J Pharmacol 2006; 538: 108-14.
27. Sullivan M, Angelini GD, Mikhailidis DP, Morgan RJ, Thompson CS, Jeremy JY. Differential changes of prostaglandin and cyclic nucleotide formation in the corpus cavernosum of the diabetic rabbit. Br J Urol 1998; 82: 578-84.
28. Miller M, Morgan RJ, Thompson CS, Mikhailidis DP, Jeremy JY. Adenylate and guanylate cyclase activity in the penis and aorta of the diabetic rat. Br J Urol 1994; 74: 106-11.
29. Sullivan ME, Thompson CS, Dashwood MR, Khan M, Mikhailidis DP, Jeremy JY, et al. Nitric oxide and erection: Is erectile dysfunction another manifestation of vascular disease? Cardiovasc Res 1999; 43: 580-94.
30. Shukla N, Thompson CS, Angelini GD, Mikhailidis DP, Jeremy JY. Homocysteine augments the reduction of endothelium dependent relaxation and cGMP formation in diabetic rabbits. Diabetologia 2002; 45: 1325-31.
31. Shukla N, Maher J, Masters J, Angelini GD, Jeremy JY. Does oxidative stress change ceruloplasmin from a protective to a vasculopathic risk factor? Atherosclerosis 2006; 187: 238-50.
32. Shukla N, Angelini GD, Jeremy JY. Interactive effects of homocysteine and copper on angiogenesis in porcine isolated saphenous vein. Ann Thorac Surg 2007; 84: 43-9.
33. Hultberg B, Andersson A, Isaksson A. The cell-damaging effects of low amounts of homocysteine and copper ions in human cell line cultures are caused by oxidative stress. Toxicology 1997; 123: 33-40.
34. Burkitt J. A critical overview of the chemistry of copper-dependent low density lipoprotein oxidation: Roles of lipid hydroperoxides, alpha-tocopherol, thiols, and ceruloplasmin. Arch Biochem Biophys 2001; 394: 117-35.
35. Shukla N, Thompson C, Angelini GD, Mikhailidis DP, Jeremy JY. Low concentrations of copper augment the impairment of endothelium-dependent relaxation of aortae from diabetic rabbits. Metabolism 2004; 53: 1315-21.
36. Corbin JD. Mechanisms of action of PDE5 inhibition in erectile dysfunction. Int J Impot Res 2004; 16 (Suppl 1): S4-7.
37. Blount MA, Zoraghi R, Bessay EP, Beasley EP, Francis SH, Corbin JD. Conversion of phosphodiesterase-5 (PDE5) catalytic site to higher affinity by PDE5 inhibitors. J Pharmacol Exp Ther 2007; 323: 730-7.
38. Clements PJ, Seibold JR, Furst DE, Mayes M, White B, Wigley F, et al High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial: Lessons learned. Semin Arthritis Rheum 2004; 33: 249-63.
39. Ogihara H, Ogihara T, Miki M, Yasuda H, Mino M. Plasma copper and antioxidant status in Wilson's disease. Pediatr Res 1995; 37: 219-26.
40. Wald DS, Morris JK, Law M, Wald NJ. Folic acid, homocysteine, and cardiovascular disease: Judging causality in the face of inconclusive trial evidence. Br Med J 2006; 333: 1114-7.
41. Antoniades C, Shirodaria C, Warrick N, Cai S, de Bono J, Lee J, et al 5-methyltetrahydrofolate rapidly improves endothelial function and decreases superoxide production in human vessels: Effects on vascular tetrahydrobiopterin availability and endothelial nitric oxide synthase coupling. Circulation 2006; 114: 1193-201.
42. Brioni JD, Nakane M, Hsieh GC, Moreland RB, Kolasa T, Sullivan JP. Activators of soluble guanylate cyclase for the treatment of male erectile dysfunction. Int J Impot Res 2002; 14: 8-14.